Monoclonal anti-CD95L (cluster of differentiation 95 ligand) antibody

US11014991B2 · kind B2 · utility

Assignee

• APOGENIX AG · DE

Inventors

• Christian Gieffers · Dossenheim, DE
• Oliver Hill · Neckarsteinach, DE
• Meinolf Thiemann · Schriesheim, DE
• Jaromir Sykora · Heppenheim, DE
• Christian Merz · Neckarsteinach, DE
• Tim SCHNYDER · Igersheim, DE
• Harald Fricke · Mannheim, DE

Key dates

• Filing date: Sep 26, 2019
• Grant date: May 25, 2021
• Expiry date: Sep 26, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to a specific CD95L antibody and to the use thereof in the treatment or diagnosis of diseases involving CD95L-induced signalling, e.g. cancer diseases.